抗原発現癌におけるCHP-HER2およびCHP-NY-ESO-1タンパク質とOK-432の併用療法の安全性および免疫原性

基本情報

NCT ID

NCT00291473

ステータス

完了

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

9

治験依頼者名

Ludwig Institute for Cancer Research

概要

Mixed cancer vaccines, CHP-HER2 protein and CHP-NY-ESO-1 protein, are to be studied to evaluate the safety and immune responses in patients who are positive either or both antigens. Nine patients will be enrolled, who are refractory to standard therapies for cancer or at high risk to relapse. CHP-HER2 and CHP-NY-ESO-1 are subcutaneously given on bimonthly basis, together with OK-432(Picibanil) as an immunoadjuvant. Six doses will be given. Toxicity profiles will be monitored, and antigen specific humoral anad T cell responses will be described.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)